GLIMEPIRIDE
It is a hypoglycaemic agent belonging to the second generation sulfonylureas. It appears to lower blood glucose by stimulating insulin release from beta cells in the pancreatic islets possibly due to increased intracellular cAMP.Non-insulin dependent diabetes.
Initially 1 mg once daily is given. Based on regular blood sugar monitoring, titration in dose is carried out step wise at intervals of 1 to 2 weeks.
Hypersensitivity. Pregnancy and lactation.
Not to operate machinery or vehicle.
Hypoglycaemia, temporary visual impairment, gastrointestinal disturbences.
Insulin and other oral antidiabetics, ACE inhibitors, allopurinol anabolic steroids and male sex hormones, chloramphenicol, coumarin derivatives, cyclophosphamide, disopyramide, fenfluramine, fluoxetine, guanethidine, ifosfamide, MAO inhibitors, miconazole, phenylbutazone, oxyphenbutazone, probenecid causes potentiation of hypoglycaemic effect.
